Boston Scientific reports Q1 adjusted EPS 56c, consensus 51c

Reports Q1 revenue $3.86B, consensus $3.69B. “Our exceptional results this quarter were fueled by our talented global team and the strength of our diversified businesses and pipeline, including the initial U.S. launch of the FARAPULSE(TM) Pulsed Field Ablation System,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific. “We continue to invest for the long term in our innovative portfolio and clinical science to benefit patients globally while delivering differentiated financial performance.”